A new drug for specific dermatitis (AD) itching! New anti-inflammatory drug: IL-31 receptor A targeted blocking antibody nemolizumab Phase III clinical success!

!--webeditor:page title"--Twitterderitis (Photo: salinetherapy.com) July 12, 2020 // Maruho is a Japanese pharmaceutical company focused on the development of new drugs for dermatology, the company announced that the results of the study of the evaluation of nemolizumab's treatment of aspecific dermatitis (AD)-related itching have been published in the New England Journal of Medicine (NEJM), a leading international medical journalarticle entitled: Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus-specific dermatitis is a chronic recurrent disease; its typical symptoms itching can lead to itching-scratching circulation, while itching-scratching circulation may cause mechanical damage to the skin, exacerbate inflammatory response, aggravate itching and affect quality of lifethe study included 215 Japanese patients aged 13 and over who had moderate to severe itching, and a median baseline itching visual simulation scale (VAS) score of 75.4study, patients were randomly assigned at a ratio of 2:1 and treated with subcutaneous injectionne nemolyzumab or placebo every 4 weeks until week 16 (nemolyzumab group, n,143; placebo group, n s 72)the study, patients were using local anti-inflammatory drugs at the same timeresults showed that the study reached the main efficacy endpoint: the rate of change relative to baseline screening of VAS scores in the 16th week of treatment, -42.8% in the nemolyzumab group and -21.4% in the placebo group, with statistically significant differences (p.001), the study reached several secondary endpointsreported a reduction in daily itching VAS scores from baseline check to 4 weeks after administration from baseline check-up to administration (nemolizumab group, -10.3%; placebo group, -4.4%) as early as the second day after the first drug administrationin week 16, the eczema area and severity index (EASI) in the nemolizumab group changed by -45.9% and the placebo group was -33.2%the percentage of patients with a quality of life index (DLQI) score of 4, 40 percent in the nemolizumab group and 22 percent in the placebo grouppercentage of patients with a score of 7 on the Insomnia Severity Index (ISI), 55 percent in the nemolizumab group and 21 percent in the placebo groupoverall, 71 percent of patients in both groups reported adverse events;3 patients in the nemolizumab group had severe adverse reactions (Menierdisease, acute pancreatitis, adhesion dermatitis)Three patients in thenemolizumab group reported four adverse treatment-related events that led to the interruption of the experimental drug: terioderitis, Menierdisease, hair loss, peripheral edema The most common adverse reactions in the were exacerbated teriotomy, which was 24% and 21% in the nemolizumab group and 21% in the placebo group, respectively The incidence of injection-related responses in the nemolizumab group was 8% and the placebo group was 3% thymusand and activation-regulating chemo-factor (TARC) only increased in the nemolizumab group, but this increase was not associated with changes in EASI "Itching reduces the quality of life of patients with tertomatitis, including work and school attention difficulties and sleep disorders," said Kenji Kabashima, First Author of the Article and Ph.D., Department of Dermatology, Graduate School of Medicine, Kyoto University important results of this study can help identify the mechanisms of itching associated with adhesion dermatitis nemolizumab may help reduce the suffering and social loss of patients with termatitis and their families Yasuhiko Kito, director of the " Maruho Board of Directors and Executive Officer of Medical Affairs, said: "In this study, the effects of nemolizumab on itching in patients with tertomatitis have been confirmed in Japanese patients by developing nemolizumab, Maruho will help improve the quality of life of patients who are itchy due to specific dermatitis "nemolizumab is a humanized monoclonal antibody that targets blocking the IL-31 receptor A, which was developed by Chinese and foreign pharmaceuticals at the end of September 2016, Maruho obtained the right to develop and commercialize nemolizumab for dermatodsines in the Japanese market from a Chinese and foreign pharmaceutical licensing authority IL-31 is a cytokine that induces itching and is reported to be associated with the occurrence of itching in patients with epithelial dermatitis and dialysis nemolizumab was created using the proprietary antibody engineering technology ACT-Ig, which extends the biological half-life of antibodies in the blood nemolizumab is thought to inhibit the biological activity of IL-31 by competitively blocking the binding of IL-31 to its receptors -specific dermatitis (AD) is a serious chronic inflammatory skin disease characterized by intense itching, significant eczema-like change strains and dry skin the disease often occurs in infants and young children, some patients continue for life, can be due to chronic recurrent eczema-like rash, severe itching, sleep loss, dietary restrictions and psychosocial impact and seriously affect the quality of life of patients moderate to severe AD is characterized by a periversion response driven by a seed set of immune cells, type 2-assisted T cells (i.e Th2 cells) IL-31 is a cytokine released by Th2 cells that interacts with the IL-31 receptor A expressed in neurons to participate in AD-related itching, while also playing a role in AD skin inflammation and AD skin barrier destruction moderate to severe AD is characterized by protruding dry skin, skin loss manifested as erythema, immersion/papules, crust/oozing, moss-like change, worsening of the hair-like skin loss, accompanied by intense itching, scratches, and skin loss that can lead to secondary infection moderate to severe AD can have a negative impact on the patient's life, placing a heavy burden on the patient, especially itching, sleep deprivation and depression (!--/ewebeditor: !--ewebeditor: !-- !-- .